Endocrine Abstracts

BackgroundUse of Evolocumab as a monotherapy or in combination with other lipid lowering drugs reduces LDL-C by up to 60% in patients with or without familial hypercholesterolemia (FH), diabetes mellitus (DM), or coronary artery disease (CAD). Data regarding the efficacy of PCSK9 inhibitors in MENA populations is lacking.MethodRetrospective case review of all patients initiated on Evolocumab treatment at Impe...

Background: Inclisiran is the first clinically available small interfering RNA (siRNA)-based treatment, has been shown to reduce pro-atherogenic lipoproteins in patients with or without familial hypercholesterolemia (FH), diabetes mellitus (DM), or atherosclerotic cardiovascular disease (ASCVD), but has not been evaluated in Middle Eastern populations.Methods: Retrospective review of patients initiating inclisiran treatment for any indication at our cent...

Purpose: Inclisiran is the first small interfering RNA (siRNA)-based treatment approved to reduce pro-atherogenic lipoproteins in patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C). We report, to the best of our knowledge, the first evaluation of its effects in a Middle Eastern population.Methods: Retrosp...

Background: Normocalcaemic primary hyperparathyroidism (NPHPT) can be considered as an early biochemical manifestation of hypercalcaemic primary hyperparathyroidism (PHPT). Vitamin D repletion and exclusion of other conditions is recommended before diagnosing NPHPT. It is often challenging to distinguish Vitamin D deficiency associated secondary hyperparathyroidism (SHPT) from NPHPT and the two conditions may coexist. A parathyroid function (PF) index [(Parathyroid hormone (PT...